MedTrace Logo

BCAA Supplementation for Concussion

NCT01860404 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-05-14

Study results available
· View outcomes & findings →

Summary

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAA's) in the treatment of concussion. The aim of the study is to determine whether, compared to placebo treatment, administration of BCAA's, at one or more doses, after a concussion improves neurocognitive recovery at one or more time-periods post concussion.

Conditions

  • Brain Concussion

Interventions

DRUG

Branched Chain Amino Acids

The three BCAA's will be combined together and dissolved in a flavored solution.

DRUG

Placebo solution

The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.

Sponsors & Collaborators

Principal Investigators

  • Sage Myers, MD · Children's Hospital of Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
34 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01860404 on ClinicalTrials.gov